JPMorgan says own this drug stock. It’s one Jim Cramer is itching to buy again

JPMorgan Says Own This Drug Stock—It’s One Jim Cramer Is Itching to Buy Again

Wall Street heavyweight JPMorgan has given a strong endorsement to a pharmaceutical stock that has caught the attention of investors—and one that famed market commentator Jim Cramer is eager to buy again. The stock in question belongs to Eli Lilly & Co. (NYSE: LLY), a leading player in the pharmaceutical industry known for its blockbuster diabetes and weight-loss drugs.

JPMorgan’s Bullish Call

JPMorgan recently reiterated its Overweight rating on Eli Lilly, citing the company’s strong pipeline, revenue growth, and dominance in the booming GLP-1 drug market. The firm raised its price target on the stock, forecasting significant upside potential as demand for weight-loss treatments like Mounjaro and Zepbound continues to surge.

Analysts at JPMorgan highlighted Eli Lilly’s ability to capitalize on the growing trend of obesity treatments, a market projected to reach $100 billion by 2030. With regulatory approvals expanding globally and new indications being explored, the investment bank sees Lilly as a must-own stock in the healthcare sector.

Jim Cramer’s Interest in the Stock

CNBC’s Jim Cramer, known for his stock-picking prowess and bold calls on "Mad Money," has expressed renewed interest in Eli Lilly. After previously taking profits, Cramer recently signaled his intention to jump back in, citing the company's sustained growth trajectory and innovation in weight-loss treatments.

"Lilly’s obesity drugs are changing the game, and the demand isn’t going away anytime soon," Cramer stated. "The stock might seem expensive, but with its earnings power and leadership in this space, it’s one I’m itching to buy again."

Why Investors Are Paying Attention

Eli Lilly’s recent earnings report exceeded expectations, reinforcing bullish sentiment around the stock. The company reported strong double-digit revenue growth, driven by increasing prescriptions for its GLP-1 drugs. Additionally, its Alzheimer’s treatment, donanemab, has shown promising results, adding another catalyst to the stock’s long-term potential.

Despite its high valuation, analysts argue that Eli Lilly’s continued expansion into new therapeutic areas and its dominance in weight-loss drugs make it a compelling investment. JPMorgan’s endorsement, coupled with Cramer’s enthusiasm, could further fuel investor interest.

Bottom Line

JPMorgan’s call to own Eli Lilly aligns with the broader market sentiment that the company is well-positioned for long-term growth. With Jim Cramer hinting at a potential re-entry, the stock could gain even more traction among retail and institutional investors alike. As obesity and diabetes treatment markets continue to expand, Eli Lilly remains a dominant force—one that Wall Street believes is worth holding onto.

For investors looking for exposure to the pharmaceutical sector, Eli Lilly appears to be a top contender—one that has both analyst backing and the attention of a seasoned market veteran like Cramer.